BG105097A - Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders - Google Patents
Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disordersInfo
- Publication number
- BG105097A BG105097A BG105097A BG10509700A BG105097A BG 105097 A BG105097 A BG 105097A BG 105097 A BG105097 A BG 105097A BG 10509700 A BG10509700 A BG 10509700A BG 105097 A BG105097 A BG 105097A
- Authority
- BG
- Bulgaria
- Prior art keywords
- apnea
- disorders
- norcisapride
- bulimia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8922598P | 1998-06-15 | 1998-06-15 | |
US12223699P | 1999-03-01 | 1999-03-01 | |
PCT/US1999/013100 WO1999065490A2 (en) | 1998-06-15 | 1999-06-10 | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BG105097A true BG105097A (en) | 2002-02-28 |
Family
ID=26780367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG105097A BG105097A (en) | 1998-06-15 | 2000-12-27 | Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders |
Country Status (24)
Country | Link |
---|---|
US (2) | US6559165B1 (ko) |
EP (1) | EP1087765B1 (ko) |
JP (1) | JP2003522103A (ko) |
KR (3) | KR20060020739A (ko) |
CN (1) | CN1312716A (ko) |
AR (1) | AR020327A1 (ko) |
AT (1) | ATE291916T1 (ko) |
AU (1) | AU764474B2 (ko) |
BG (1) | BG105097A (ko) |
BR (1) | BR9911302A (ko) |
CA (1) | CA2334369A1 (ko) |
CZ (1) | CZ20004736A3 (ko) |
DE (1) | DE69924488T2 (ko) |
ES (1) | ES2237117T3 (ko) |
HK (1) | HK1040059A1 (ko) |
HU (1) | HUP0102026A3 (ko) |
IL (1) | IL140117A0 (ko) |
IS (1) | IS5755A (ko) |
NO (1) | NO20006358L (ko) |
NZ (3) | NZ526108A (ko) |
PL (1) | PL345325A1 (ko) |
SK (1) | SK19062000A3 (ko) |
TR (6) | TR200103762T2 (ko) |
WO (1) | WO1999065490A2 (ko) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7160898B2 (en) * | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US7846180B2 (en) | 1999-06-22 | 2010-12-07 | Ethicon Endo-Surgery, Inc. | Tissue fixation devices and methods of fixing tissue |
US6821285B2 (en) | 1999-06-22 | 2004-11-23 | Ndo Surgical, Inc. | Tissue reconfiguration |
US8287554B2 (en) | 1999-06-22 | 2012-10-16 | Ethicon Endo-Surgery, Inc. | Method and devices for tissue reconfiguration |
US6835200B2 (en) | 1999-06-22 | 2004-12-28 | Ndo Surgical. Inc. | Method and devices for tissue reconfiguration |
US6663639B1 (en) | 1999-06-22 | 2003-12-16 | Ndo Surgical, Inc. | Methods and devices for tissue reconfiguration |
EP1833467B1 (en) | 2004-12-20 | 2016-08-03 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
GB0524668D0 (en) * | 2005-12-02 | 2006-01-11 | Novartis Ag | Organic compounds |
US8852216B2 (en) | 2007-03-23 | 2014-10-07 | Ethicon Endo-Surgery, Inc. | Tissue approximation methods |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR748807A (fr) | 1932-03-10 | 1933-07-10 | Gulf Refining Co | Perfectionnements à la fabrication d'hydrocarbures |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US5057525A (en) | 1981-10-01 | 1991-10-15 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives |
US5137896A (en) | 1981-10-01 | 1992-08-11 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
CA1183847A (en) | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
US4962115A (en) | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
US4598123A (en) | 1983-07-14 | 1986-07-01 | Unites States Steel Corporation | Impact modified methyl methacrylate polymer |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4800162A (en) | 1987-04-01 | 1989-01-24 | Sepracor, Inc. | Method for resolution of steroisomers in multiphase and extractive membrane reactors |
US5057427A (en) | 1988-04-07 | 1991-10-15 | Sepracor, Inc. | Method for resolution of stereoisomers |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
GB8823980D0 (en) * | 1988-10-13 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
US5116407A (en) | 1988-10-13 | 1992-05-26 | Courtaulds Coatings Limited | Antifouling coatings |
JPH02188523A (ja) | 1989-01-13 | 1990-07-24 | M S C:Kk | 睡眠時無呼吸症治療薬 |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5075290A (en) | 1989-06-28 | 1991-12-24 | University Of Virginia Alumni Patents Foundation | Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5356934A (en) | 1990-03-29 | 1994-10-18 | Eli Lilly And Company | Selected serotonin subtype receptor agonist to treat sleep apnea |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
DE69226961T2 (de) * | 1991-12-21 | 1999-04-29 | Smithkline Beecham P.L.C., Brentford, Middlesex | Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
CA2139638A1 (en) | 1992-07-07 | 1994-01-20 | Nancy M. Gray | Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
WO1994001111A1 (en) | 1992-07-07 | 1994-01-20 | Sepracor Inc. | Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
GB9310756D0 (en) * | 1993-05-25 | 1993-07-14 | Glaxo Lab Sa | Compositions |
CA2166730A1 (en) | 1993-07-06 | 1995-01-19 | Robert T. Sims | H2 antagonist-gastrointestinal motility agent combinations |
US5502067A (en) | 1994-02-04 | 1996-03-26 | Morgan; Julia A. | Treating apneahypopnea/snoring in humans |
US5407953A (en) | 1994-02-04 | 1995-04-18 | Morgan; Julia A. | Treating apnea/hypopnea/snoring in humans |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5712293A (en) | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
FR2735475B1 (fr) * | 1995-06-13 | 1997-07-11 | Synthelabo | Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique |
US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
EA002362B1 (ru) * | 1997-07-11 | 2002-04-25 | Янссен Фармацевтика Н.В. | Применение (+)-4-амино-5-хлор-n-(3-метокси-4-пиперидинил)-2-метоксибензамида для приготовления лекарственных препаратов для лечения заболеваний желудочно-кишечного тракта |
TR200103056T2 (tr) | 1998-06-15 | 2002-06-21 | Sepracor Inc. | Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı. |
-
1999
- 1999-06-10 SK SK1906-2000A patent/SK19062000A3/sk unknown
- 1999-06-10 DE DE69924488T patent/DE69924488T2/de not_active Expired - Fee Related
- 1999-06-10 TR TR2001/03762T patent/TR200103762T2/xx unknown
- 1999-06-10 EP EP99930196A patent/EP1087765B1/en not_active Expired - Lifetime
- 1999-06-10 CN CN99809564A patent/CN1312716A/zh active Pending
- 1999-06-10 IL IL14011799A patent/IL140117A0/xx unknown
- 1999-06-10 TR TR2001/03758T patent/TR200103758T2/xx unknown
- 1999-06-10 TR TR2001/03759T patent/TR200103759T2/xx unknown
- 1999-06-10 BR BR9911302-3A patent/BR9911302A/pt not_active Application Discontinuation
- 1999-06-10 CZ CZ20004736A patent/CZ20004736A3/cs unknown
- 1999-06-10 AU AU46784/99A patent/AU764474B2/en not_active Ceased
- 1999-06-10 TR TR2001/03760T patent/TR200103760T2/xx unknown
- 1999-06-10 PL PL99345325A patent/PL345325A1/xx not_active Application Discontinuation
- 1999-06-10 HU HU0102026A patent/HUP0102026A3/hu unknown
- 1999-06-10 WO PCT/US1999/013100 patent/WO1999065490A2/en not_active Application Discontinuation
- 1999-06-10 NZ NZ526108A patent/NZ526108A/en unknown
- 1999-06-10 KR KR1020067003048A patent/KR20060020739A/ko not_active Application Discontinuation
- 1999-06-10 JP JP2000554370A patent/JP2003522103A/ja active Pending
- 1999-06-10 ES ES99930196T patent/ES2237117T3/es not_active Expired - Lifetime
- 1999-06-10 AT AT99930196T patent/ATE291916T1/de not_active IP Right Cessation
- 1999-06-10 CA CA002334369A patent/CA2334369A1/en not_active Abandoned
- 1999-06-10 TR TR2001/03757T patent/TR200103757T2/xx unknown
- 1999-06-10 NZ NZ535055A patent/NZ535055A/en unknown
- 1999-06-10 KR KR1020067010978A patent/KR20060067985A/ko not_active Application Discontinuation
- 1999-06-10 KR KR1020007014025A patent/KR20010052740A/ko not_active Application Discontinuation
- 1999-06-10 TR TR2000/03707T patent/TR200003707T2/xx unknown
- 1999-06-15 AR ARP990102864A patent/AR020327A1/es unknown
-
2000
- 2000-11-28 US US09/722,391 patent/US6559165B1/en not_active Expired - Fee Related
- 2000-12-08 IS IS5755A patent/IS5755A/is unknown
- 2000-12-12 NZ NZ508825A patent/NZ508825A/en unknown
- 2000-12-13 NO NO20006358A patent/NO20006358L/no unknown
- 2000-12-27 BG BG105097A patent/BG105097A/xx unknown
-
2002
- 2002-03-06 HK HK02101726.7A patent/HK1040059A1/zh unknown
-
2003
- 2003-02-26 US US10/372,875 patent/US7064138B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG105096A (en) | Use of optically pure(+)norcisapride for treaing apnea, bulimia and other disorders | |
IL256054A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
MXPA04001525A (es) | Analogos de peptido -1 similar al glucagon. | |
JO2311B1 (en) | Alkyl inhibitors Ariel phosphodiesterase-4 | |
EA200300026A1 (ru) | Аналоги глюкагоноподобного пептида-1 | |
PL323825A1 (en) | Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin | |
MY139566A (en) | Imidazolopyridines and methods of making and using the same | |
PL316658A1 (en) | Novel application of serotonin antagonists | |
AU3111695A (en) | Substituted pyrimidine compounds and the use thereof | |
AU3111595A (en) | The use of thiazole and thiadiazole compounds | |
AU3111395A (en) | Triazole compounds and the use thereof | |
DE60322417D1 (en) | 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren | |
BG105097A (en) | Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders | |
SG117434A1 (en) | Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease | |
WO2000051582A3 (en) | Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron | |
AU2634597A (en) | Compounds with growth hormone releasing properties | |
IL115589A0 (en) | Use of cck-b antagonists in pharmaceutical compositions | |
WO2000010554A3 (en) | Methods and compositions employing optically pure s(+) vigabatrin | |
GB2389532A (en) | The method of treating cancer | |
CA2260863A1 (en) | Treatment of psychotic disorders | |
DE60009315D1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
EP1464333A3 (en) | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders | |
EP1468685A3 (en) | Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders | |
AU2525201A (en) | Combination of cyamemazine and an atypical neuroleptic | |
GB2368524B (en) | Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders |